A Dark Vector Cognition product

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

40K characters. Original on sec.gov ·

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities

Litigation Reform Act of 1995, we

provide the following cautionary remarks regarding important factors

that, among others, could cause future results

to differ materially from the forward-looking statements, expectations and assumptions

expressed or implied

herein.

All forward-looking statements made by us are subject to

risks and uncertainties and are not guarantees of

future performance.

These forward-looking statements involve known and unknown

risks, uncertainties and other

factors that may cause our actual results, performance and achievements

or industry results to be materially

different from any future results, performance or achievements expressed or implied by such

forward-looking

statements.

These statements are generally identified by the use of such

terms as “may,” “could,” “expect,”

“intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,”

“to be,” “to make” or other comparable

terms.

Factors that could cause or contribute to such differences include, but are not limited

to, those discussed in

the documents we file with the Securities and Exchange Commission

(SEC), including our Annual Report on Form

10-K.

Forward looking statements include the overall impact of the Novel Coronavirus

Disease 2019 (COVID-19)

on us, our results of operations, liquidity and financial condition (including

any estimates of the impact on these

items), the rate and consistency with which dental and other practices

resume or maintain normal operations in the

United States and internationally, expectations regarding PPE products and COVID-19 related product sales and

inventory levels, whether additional resurgences or variants of the virus will adversely impact

the resumption of

normal operations, whether supply chain disruptions will adversely impact

our business, the impact of integration

and restructuring programs as well as of any future acquisitions, general economic

conditions including exchange

rates, inflation and recession, and more generally current expectations

regarding performance in current and future

periods.

Forward looking statements also include the (i) our ability to

have continued access to a variety of

COVID-19 test types and expectations regarding COVID-19

test sales, demand and inventory levels and (ii)

potential for us to distribute the COVID-19 vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from current

and historical results

include, but are not limited to: risks associated with COVID-19

and any variants thereof, as well as other disease

outbreaks, epidemics, pandemics, or similar wide-spread public health concerns

and other natural disasters; our

dependence on third parties for the manufacture and supply of our products;

our ability to develop or acquire and

maintain and protect new products (particularly technology products) and

technologies that achieve market

acceptance with acceptable margins; transitional challenges associated with acquisitions,

dispositions and joint

ventures, including the failure to achieve anticipated synergies/benefits; legal, regulatory, compliance,

cybersecurity, financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions

in our governing documents that may discourage third-party acquisitions

of us; adverse changes in supplier rebates

or other purchasing incentives; risks related to the sale of corporate brand products;

effects of a highly competitive

(including, without limitation, competition from third-party online commerce

sites) and consolidating market; the

repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health

care industry;

risks from expansion of customer purchasing power and multi-tiered

costing structures; increases in shipping costs

for our products or other service issues with our third-party shippers; general

global and domestic macro-economic

and political conditions, including inflation, deflation, recession, fluctuations

in energy pricing and the value of the

U.S. dollar as compared to foreign currencies, and changes to other economic

indicators, international trade

agreements, potential trade barriers and terrorism; failure to comply with existing

and future regulatory

requirements; risks associated with the EU Medical Device Regulation; failure

to comply with laws and regulations

relating to health care fraud or other laws and regulations;

failure to comply with laws and regulations relating to

the collection, storage and processing of sensitive personal information

or standards in electronic health records or

transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims;

litigation risks;

new or unanticipated litigation developments and the status of litigation

matters; risks associated

with customs policies or legislative import restrictions; cyberattacks

or other privacy or data security breaches; risks

associated with our global operations; our dependence on our senior management,

employee hiring and retention,

and our relationships with customers, suppliers and manufacturers;

and disruptions in financial markets.

The order

in which these factors appear should not be construed to indicate their

relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control

or predict.

Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction

of actual results.

We undertake no duty and have no obligation to update forward-looking statements except as

required by law.

Where You

Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public

conference calls and webcasts, press releases, the investor relations

page of our website (www.henryschein.com)

and the social media channels identified on the Newsroom page of our website.

Recent Developments

During the year ended December 31, 2022 we experienced a decrease

in the sales of PPE and COVID-19 test kits.

During the three months ended April 1, 2023, we continued to experience

a decrease in the sales of PPE and

COVID-19 test kits compared with the same period in the prior

year and we expect further decreases in sales in

2023 compared to the prior year.

The impact from inflation, including manufacturer price increases excluding PPE

products, was slightly more

pronounced in Europe than in North America.

Though inflation impacts both our revenues and costs, the

depth and

breadth of our product portfolio often allows us to offer lower-cost national brand solutions or

corporate brand

alternatives to our more price-sensitive customers who are unable

to absorb price increases, thus positioning us to

protect our gross profit.

Our condensed consolidated financial statements reflect estimates and

assumptions made by us that affect, among

other things, our goodwill, long-lived asset and definite-lived intangible

asset valuation; inventory valuation; equity

investment valuation; assessment of the annual effective tax rate; valuation of

deferred income taxes and income

tax contingencies; the allowance for doubtful accounts; hedging activity;

supplier rebates; measurement of

compensation cost for certain share-based performance awards and cash bonus

plans; and pension plan

assumptions.

There is an ongoing risk that the consequences of the COVID-19

pandemic may again have a

material adverse effect on our business, results of operations and cash flows and may

result in a material adverse

effect on our financial condition and liquidity.

However, the extent of the potential impact cannot be reasonably

estimated at this time.

Executive-Level Overview

Henry Schein, Inc. is a solutions company for health care professionals powered

by a network of people and

technology.

We believe we are the world’s

largest provider of health care products and services primarily to office-

based dental and medical practitioners, as well as alternate sites of care.

We

serve more than one million customers

worldwide including dental practitioners, laboratories, physician practices, and

ambulatory surgery centers, as well

as government, institutional health care clinics and other alternate care clinics.

We

believe that we have a strong

brand identity due to our more than 90 years of experience distributing health

care products.

We are headquartered in Melville, New York,

employ more than 22,000 people (of which approximately 10,700

are

based outside of the United States) and have operations or affiliates in 32 countries

and territories.

Our broad

global footprint has evolved over time through our organic success as well as

through contribution from strategic

acquisitions.

We

have established strategically located distribution centers around

the world to enable us to better serve our

customers and increase our operating efficiency.

This infrastructure, together with broad product and service

offerings at competitive prices, and a strong commitment to customer service, enables

us to be a single source of

supply for our customers’ needs.

While our primary go-to-market strategy is in our capacity as a distributor, we also market and sell our own

corporate brand portfolio of cost-effective, high-quality consumable merchandise products,

manufacture certain

dental specialty products in the areas of implants, orthodontics and endodontics,

and repackage/relabel prescription

drugs and/or devices.

We

have

achieved scale in these global businesses primarily through acquisitions

as

manufacturers of these products typically do not utilize a distribution channel

to serve customers.

We

conduct our business through two reportable segments: (i) health

care distribution and (ii) technology and

value-added services.

These segments offer different products and services to the same customer base.

Our global

dental businesses serve office-based dental practitioners, dental laboratories, schools, government

and other

institutions.

Our medical businesses serve physician offices, urgent care centers, ambulatory care sites,

emergency

medical technicians, dialysis centers, home health, federal and state governments

and large enterprises, such as

group practices and integrated delivery networks, among other providers

across a wide range of specialties.

The health care distribution reportable segment, combining our global dental and

medical operating segments,

distributes consumable products, small equipment, laboratory products, large equipment, equipment

repair services,

branded and generic pharmaceuticals, vaccines, surgical products, dental specialty

products (including implant,

orthodontic and endodontic products), diagnostic tests, infection-control products,

PPE products and vitamins.

Our global technology and value-added services business provides software, technology

and other value-added

services to health care practitioners.

Our technology business offerings include practice management software

systems for dental and medical practitioners.

Our value-added practice solutions include practice consultancy,

education, revenue cycle management and financial services on a non-recourse

basis, e-services, practice

technology, network and hardware services, as well as consulting, and continuing education services for

practitioners.

A key element to grow closer to our customers is our One Schein initiative, which

is a unified go-to-market

approach that enables practitioners to work synergistically with our supply chain,

equipment sales and service and

other value-added services, allowing our customers to leverage the

combined value that we offer through a single

program.

Specifically, One Schein provides customers with streamlined access to our comprehensive offering of

national brand products, our corporate brand products and proprietary specialty

products and solutions (including

implant, orthodontic and endodontic products).

In addition, customers have access to a wide range of services,

including software and other value-added services.

Industry Overview

In recent years, the health care industry has increasingly focused on cost containment.

This trend has benefited

distributors capable of providing a broad array of products and services at low

prices.

It also has accelerated the

growth of HMOs, group practices, other managed care accounts and collective buying

groups, which, in addition to

their emphasis on obtaining products at competitive prices, tend to favor distributors

capable of providing

specialized management information support.

We

believe that the trend towards cost containment has the potential

to favorably affect demand for technology solutions, including software, which can

enhance the efficiency and

facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies

and transactions that we

undertook to expand our business, domestically and internationally, in part to address significant changes in the

health care industry, including consolidation of health care distribution companies, health care reform, trends

toward managed care, cuts in Medicare and collective purchasing arrangements.

Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented

and diverse.

The industry ranges from sole practitioners working out of

relatively small offices to group practices

or service organizations ranging in size from a few practitioners to a large number of practitioners who have

combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage

large quantities of supplies

in their offices, the distribution of health care supplies and small equipment to office-based health

care practitioners

has been characterized by frequent, small quantity orders, and a need for rapid,

reliable and substantially complete

order fulfillment.

The purchasing decisions within an office-based health care practice

are typically made by the

practitioner or an administrative assistant.

Supplies and small equipment are generally purchased from more

than

one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base.

Health care practitioners are increasingly seeking to

partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician

hospital organizations.

In many cases, purchasing decisions for consolidated groups

are made at a centralized or

professional staff level; however, orders are delivered to the practitioners’ offices.

We

believe that consolidation within the industry will continue to

result in a number of distributors, particularly

those with limited financial, operating and marketing resources, seeking to

combine with larger companies that can

provide growth opportunities.

This consolidation also may continue to result in distributors seeking

to acquire

companies that can enhance their current product and service offerings or provide

opportunities to serve a broader

customer base.

Our approach to acquisitions and joint ventures has been to expand our role as

a provider of products and services

to the health care industry.

This trend has resulted in our expansion into service areas that complement

our existing

operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired

businesses.

As industry consolidation continues, we believe that we are positioned

to capitalize on this trend, as we believe we

have the ability to support increased sales through our existing infrastructure, although

there can be no assurances

that we will be able to successfully accomplish this.

We

also have invested in expanding

our sales/marketing

infrastructure to include a focus on building relationships with decision

makers who do not reside in the office-

based practitioner setting.

As the health care industry continues to change, we continually evaluate possible

candidates for joint venture or

acquisition and intend to continue to seek opportunities to expand our

role as a provider of products and services to

the health care industry.

There can be no assurance that we will be able to successfully pursue

any such

opportunity or consummate any such transaction, if pursued.

If additional transactions are entered into or

consummated, we would incur merger and/or acquisition-related costs, and there

can be no assurance that the

integration efforts associated with any such transaction would be successful.

Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth

due to the aging population,

increased health care awareness, the proliferation of medical technology

and testing, new pharmacology treatments,

and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance

coverage.

In addition, the physician market continues to benefit from

the shift of procedures and diagnostic testing

from acute care settings to alternate-care sites, particularly physicians’

offices.

According to the U.S. Census Bureau’s International Database, between 2023 and 2033, the 45 and older

population is expected to grow by approximately 11%.

Between 2023 and 2043, this age group is expected to grow

by approximately 21%.

This compares with expected total U.S. population growth

rates of approximately 6%

between 2023 and 2033 and approximately 11% between 2023 and 2043.

According to the U.S. Census Bureau’s International Database, in 2023 there are approximately seven million

Americans aged 85 years or older, the segment of the population most in need of long-term care

and elder-care

services.

By the year 2050, that number is projected to nearly triple to approximately

19 million.

The population

aged 65 to 84 years is projected to increase by approximately 23% during

the same period.

As a result of these market dynamics, annual expenditures for health

care services continue to increase in the

United States.

We believe that demand for our products and services will grow while continuing to be impacted by

current and future operating, economic, and industry conditions.

The Centers for Medicare and Medicaid Services,

or CMS, published “National Health Expenditure Data” indicating that

total national health care spending reached

approximately $4.3 trillion in 2021, or 18.3% of the nation’s gross domestic product, the benchmark

measure for

annual production of goods and services in the United States.

Health care spending is projected to reach

approximately $6.8 trillion by 2030, or 19.6% of the nation’s projected gross domestic product.

Government

Certain of our businesses involve the distribution, manufacturing, importation,

exportation, marketing and sale of,

and/or third party payment for, pharmaceuticals and/or medical devices, and in this regard, we are subject

to

extensive local, state, federal and foreign governmental laws and regulations,

including as applicable to our

wholesale distribution of pharmaceuticals and medical devices, manufacturing

activities, and as part of our

specialty home medical supply business that distributes and sells medical equipment

and supplies directly to

patients.

Federal, state and certain foreign governments have also increased enforcement

activity in the health care

sector, particularly in areas of fraud and abuse, anti-bribery and corruption, controlled substances handling,

medical

device regulations and data privacy and security standards.

Certain of our businesses are subject to various additional federal, state,

local and foreign laws and regulations,

including with respect to the sale, transportation, storage, handling and

disposal of hazardous or potentially

hazardous substances, and safe working conditions.

In addition, certain of our businesses must operate in

compliance with a variety of burdensome and complex billing and record-keeping

requirements in order to

substantiate claims for payment under federal, state and commercial healthcare

reimbursement programs.

One of

these businesses was suspended in October 2021 by CMS from receiving

payments from Medicare, although it was

permitted to continue to perform and bill for Medicare services.

Such suspension was terminated on September 30,

Government and private insurance programs fund a large portion of the total cost of medical care,

and there have

been efforts to limit such private and government insurance programs, including efforts, thus far

unsuccessful, to

seek repeal of the entire United States Patient Protection and Affordable Care Act,

as amended by the Health Care

and Education Reconciliation Act, each enacted in March 2010 (as amended,

the “ACA”).

In addition, activities to

control medical costs, including laws and regulations lowering reimbursement

rates for pharmaceuticals, medical

devices and/or medical treatments or services, are ongoing.

Many of these laws and regulations are subject to

change and their evolving implementation may impact our operations and our

financial performance.

Our businesses are generally subject to numerous laws and regulations that could

impact our financial performance,

and failure to comply with such laws or regulations could have a material adverse

effect on our business.

A more detailed discussion of governmental laws and regulations

is included in Management’s Discussion &

Analysis of Financial Condition and Results of Operations, contained

in our Annual Report on Form 10-K for the

fiscal year ended December 31, 2022, filed with the SEC on February 21, 2023.

Results of Operations

The following tables summarize the significant components of our operating

results and cash flows for the three

months ended April 1, 2023 and March 26, 2022:

Three Months Ended

April 1,

March 26,

2023

2022

Operating results:

Net sales

$

3,060

$

3,179

Cost of sales

2,094

2,206

Gross profit

Operating expenses:

Selling, general and administrative

Depreciation and amortization

Restructuring costs

-

Operating income

$

$

Other expense, net

$

(12)

$

(5)

Net income

Net income attributable to Henry Schein, Inc.

Three Months Ended

April 1,

March 26,

2023

2022

Cash flows:

Net cash provided by operating activities

$

$

Net cash used in investing activities

(39)

(27)

Net cash provided by (used in) financing activities

(62)

Plan of Restructuring

On August 1, 2022, we committed to a restructuring plan focused on

funding the priorities of the strategic plan and

streamlining operations and other initiatives to increase efficiency.

We expect this initiative to extend through

We are currently unable in good faith to make a determination of an estimate of the amount or range of

amounts expected to be incurred in connection with these activities, both with

respect to each major type of cost

associated therewith and with respect to the total cost, or an estimate of

the amount or range of amounts that will

result in future cash expenditures.

During the three months ended April 1, 2023, we recorded restructuring costs of

$30 million primarily related to

severance and employee-related costs, accelerated amortization of right-of-use

lease assets and fixed assets, and

other lease exit costs.

This amount also includes $1 million related to the disposal

of an unprofitable U.S. business,

initiated during 2022 and completed during the three months ended April

1, 2023.

Three Months Ended April 1, 2023 Compared to Three Months Ended March 26, 2022

Net Sales

Net sales were as follows:

April 1,

% of

March 26,

% of

Increase / (Decrease)

2023

Total

2022

Total

$

%

Health care distribution

(1)

Dental

$

1,898

62.0

%

$

1,828

57.5

%

$

3.8

%

Medical

31.8

1,172

36.9

(201)

(17.2)

Total health care distribution

2,869

93.8

3,000

94.4

(131)

(4.4)

Technology and value-added services

(2)

6.2

5.6

6.8

Total

$

3,060

100.0

%

$

3,179

100.0

%

$

(119)

(3.8)

%

The components of our sales growth were as follows:

Total Local

Currency

Growth

Foreign

Exchange

Impact

Total Sales

Growth

Local Currency Growth

Local Internal

Growth

Acquisition

Growth

Health care distribution

(1)

Dental Merchandise

4.0

%

2.5

%

6.5

%

(2.4)

%

4.1

%

Dental Equipment

3.9

1.5

5.4

(2.6)

2.8

Total Dental

4.0

2.3

6.3

(2.5)

3.8

Medical

(17.1)

-

(17.1)

(0.1)

(17.2)

Total Health Care Distribution

(4.3)

1.4

(2.9)

(1.5)

(4.4)

Technology and value-added services

(2)

6.5

1.5

8.0

(1.2)

6.8

Total

(3.7)

%

1.4

%

(2.3)

%

(1.5)

%

(3.8)

%

Note: Percentages for Net Sales; Gross Profit; Selling, General and Administrative; Other Expense, Net; and Income Taxes are based on

actual values and may not recalculate due to rounding.

(1)

Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and

generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic

products), diagnostic tests, infection-control products, PPE products and vitamins.

(2)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,

practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing

education services for practitioners, consulting and other services.

Global Sales

Global net sales for the three months ended April 1, 2023 decreased 3.8% based

upon the components presented in

the table above.

Sales of PPE products and COVID-19 test kits for the three

months ended April 1, 2023 were

approximately $201 million, a decrease of approximately 58.8% versus

the three months ended March 26, 2022.

Excluding PPE products and COVID-19 test kits, the increase in

internally generated local currency sales was

6.3%.

Dental

Dental net sales for the three months ended April 1, 2023 increased 3.8%

based upon the components presented in

the table above.

Our sales growth in local currency for dental merchandise was primarily

attributable to stable

patient traffic along with some price increases.

Our sales growth in local currency for dental equipment was

primarily attributable to growth in North America for traditional equipment,

partially offset by a decrease in digital

equipment.

International dental equipment sales growth in local currency

was supported by a strong equipment

backlog.

Sales of PPE products for the three months ended April 1, 2023

were approximately $92 million, a

decrease of approximately 35.8% versus the three months ended March 26,

Excluding PPE products, the

increase in internally generated local currency dental sales was 7.4%.

Medical

Medical net sales for the three months ended April 1, 2023 decreased

17.2% based upon the components presented

in the table above.

The local currency decrease in medical sales is primarily attributable

to lower sales of PPE

products and COVID-19 test kits, partially offset by strong medical equipment and

pharmaceutical sales.

Sales of

PPE products and COVID-19 test kits were approximately $109 million for

the three months ended April 1, 2023, a

decrease of approximately 68.4% compared to the three months ended March

26, 2022.

Excluding PPE products

and COVID-19 test kits, the increase in internally generated local currency medical

sales was 4.2%.

Technology and value-added services

Technology and value-added services net sales for the three months ended April 1, 2023 increased 6.8% based upon

the components presented in the table above.

During the three months ended April 1, 2023,

the trend for sales of

transactional software improved as we increased the number of cloud-based

users, generating demand for our

revenue cycle management solutions which drive practice efficiency and patient engagement.

The increase in sales

during the quarter ended April 1, 2023 was partially offset by the expiration, during

the third quarter of 2022, of a

modestly profitable government contract in one of our value-added services

businesses.

Gross Profit

Gross profit and gross margin percentages by segment and in total were as follows:

April 1,

Gross

March 26,

Gross

Increase / (Decrease)

2023

Margin %

2022

Margin %

$

%

Health care distribution

$

29.2

%

$

28.6

%

$

(20)

(2.3)

%

Technology and value-added services

67.4

64.9

11.1

Total

$

31.6

$

30.6

$

(7)

(0.7)

As a result of different practices of categorizing costs associated with distribution networks

throughout our

industry, our gross margins may not necessarily be comparable to other distribution companies.

Additionally, we

realize substantially higher gross margin percentages in our technology and value-added services

segment than in

our health care distribution segment.

These higher gross margins result from being both the developer and seller of

software products and services, as well as certain financial services.

The software industry typically realizes higher

gross margins to recover investments in research and development.

Within our health care distribution segment, gross profit margins may vary from one period to the next.

Changes in

the mix of products sold as well as changes in our customer mix have been

the most significant drivers affecting

our gross profit margin.

For example, sales of our corporate brand products achieve

gross profit margins that are

higher than average total gross profit margins of all products.

With respect to customer mix, sales to our large-

group customers are typically completed at lower gross margins due to the higher

volumes sold as opposed to the

gross margin on sales to office-based practitioners, who normally purchase lower volumes.

Health care distribution gross profit decreased primarily due to the decrease

in net sales discussed above, partially

offset by $11 million of gross profit from acquisitions and gross margin expansion, mainly as a result of price

increases and a favorable impact of sales mix of higher-margin products.

Technology and value-added services gross profit increased as a result of a higher gross profit from internally

generated sales and gross profit of $3 million from acquisitions, as well as an

increase in gross margin rates

primarily due to the impact of price increases.

Operating Expenses

Operating expenses (consisting of selling, general and administrative

expenses; depreciation and amortization; and

restructuring costs) by segment and in total were as follows:

% of

% of

April 1,

Respective

March 26,

Respective

Increase

2023

Net Sales

2022

Net Sales

$

%

Health care distribution

$

24.1

%

$

21.5

%

$

7.2

%

Technology and value-added services

51.6

46.4

18.7

Total

$

25.8

$

22.9

$

8.5

The net increase in operating expenses is attributable to the following:

Restructuring Costs

Operating Costs

Acquisitions

Total

Health care distribution

$

$

$

$

Technology and value-added services

Total

$

$

$

$

The restructuring costs are primarily related to severance and employee-related

costs, accelerated amortization of

right-of-use lease assets and fixed assets, and other lease exit costs.

The increase in operating costs includes

increases in payroll and payroll related costs, travel and convention expenses

and acquisition costs in both of our

reportable segments.

While the U.S. economy has recently experienced inflationary

pressures and strengthening of

the U.S. dollar, their impacts have not been material to our results of operations.

Other Expense, Net

Other expense, net was as follows:

April 1,

March 26,

Variance

2023

2022

$

%

Interest income

$

$

$

58.3

%

Interest expense

(14)

(7)

(7)

(97.8)

Other, net

(1)

-

(1)

n/a

Other expense, net

$

(12)

$

(5)

$

(7)

(119.0)

Interest income increased primarily due to increased interest rates.

Interest expense increased primarily due to

increased borrowings and increased interest rates.

Income Taxes

For the three months ended April 1, 2023 our effective tax rate was 23.8% compared

to 24.0% for the prior year

period.

The difference between our effective tax rate and the federal statutory tax rate primarily

relates to state and

foreign income taxes and interest expense as well as stock-based compensation.

Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases

of additional noncontrolling

interests, repayments of debt principal, the funding of working capital needs,

purchases of fixed assets and

repurchases of common stock.

Working capital requirements generally result from increased sales, special

inventory forward buy-in opportunities and payment terms for receivables

and payables.

Historically, sales have

tended to be stronger during the second half of the year and special inventory

forward buy-in opportunities have

been most prevalent just before the end of the year, and have caused our working capital requirements

to be higher

from the end of the third quarter to the end of the first quarter of

the following year.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt

placements.

Please see

Note 7 – Debt

for further information.

Our ability to generate sufficient cash flows from

operations is dependent on the continued demand of our customers

for our products and services, and access to

products and services from our suppliers.

Our business requires a substantial investment in working capital, which

is susceptible to fluctuations during the

year as a result of inventory purchase patterns and seasonal demands.

Inventory purchase activity is a function of

sales activity, special inventory forward buy-in opportunities and our desired level of inventory.

We anticipate

future increases in our working capital requirements.

We finance our business to provide adequate funding for at least 12 months.

Funding requirements are based on

forecasted profitability and working capital needs, which, on occasion, may

change.

Consequently, we may change

our funding structure to reflect any new requirements.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,

and our available funds under existing credit facilities provide us with

sufficient liquidity to meet our currently

foreseeable short-term and long-term capital needs.

Net cash provided by operating activities was $27 million for the

three months ended April 1, 2023, compared to

net cash provided by operating activities of $93 million for the prior year.

The net change of $66 million was

primarily due to a decrease in operating income and an unfavorable change in

working capital, net of acquisitions.

Net cash used in investing activities was $39 million for the three months

ended April 1, 2023, compared to $27

million for the prior year.

The net change of $12 million was primarily attributable to increased payments

for

purchases of fixed assets.

Net cash provided by financing activities was $21 million for the

three months ended April 1, 2023, compared to

net cash used in financing activities of $62 million for the prior year.

The net change of $83 million was primarily

due to increased net borrowings from debt, partially offset by increased repurchases

of common stock.

The following table summarizes selected measures of liquidity and capital

resources:

April 1,

December 31,

2023

2022

Cash and cash equivalents

$

$

Working

capital

(1)

1,780

1,764

Debt:

Bank credit lines

$

$

Current maturities of long-term debt

Long-term debt

1,021

1,040

Total debt

$

1,312

$

1,149

Leases:

Current operating lease liabilities

$

$

Non-current operating lease liabilities

(1)

Includes $555 million and $327 million of certain accounts receivable which serve as security for U.S. trade accounts receivable

securitization at April 1, 2023 and December 31, 2022, respectively.

Our cash and cash equivalents consist of bank balances and investments

in money market funds representing

overnight investments with a high degree of liquidity.

Accounts receivable days sales outstanding and inventory turns

Our accounts receivable days sales outstanding from operations

increased to 43.4 days as of April 1, 2023 from

41.6 days as of March 26, 2022.

During the three months ended April 1, 2023, we wrote

off approximately $3

million of fully reserved accounts receivable against our trade receivable

reserve.

Our inventory turns from

operations decreased to 4.3 as of April 1, 2023 from 4.7 as of March 26, 2022.

Our working capital accounts may

be impacted by current and future economic conditions.

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles,

and certain equipment.

Our leases have remaining terms of less than one year to

approximately 18 years, some of

which may include options to extend the leases for up to 15 years.

As of April 1, 2023, our right-of-use assets

related to operating leases were $280 million and our current and non-current

operating lease liabilities were $73

million and $274 million, respectively.

Stock Repurchases

On February 8, 2023, our Board of Directors authorized the repurchase

of up to an additional $400 million in shares

of our common stock.

From March 3, 2003 through April 1, 2023, we repurchased $4.6 billion,

or 88,404,588 shares, under our common

stock repurchase programs, with $415 million available as of April 1, 2023

for future common stock share

repurchases.

Critical Accounting Policies and Estimates

There have been no material changes in our critical accounting policies and

estimates from those disclosed in Item

7 of our Annual Report on Form 10-K for the year ended December 31, 2022,

except accounting policies adopted

as of January 1, 2023, which are discussed in

Note 2-Critical Accounting Policies, Accounting Pronouncements

Adopted and Recently Issued Accounting Standards

of the Notes to the Condensed Consolidated Financial

Statements included under Item 1.

Accounting Standards Update

For a discussion of accounting standards updates that have been adopted

or will be adopted, see

Note 2-Critical

Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards

of the Notes

to the Condensed Consolidated Financial Statements included under Item 1.

Previous: Item 1. CONDENSED CONSOLIDATED · Next: Item 3. QUANTITATIVE